COX-2 inhibitors and risk of heart failure

被引：7

|

作者：

Kammerl, MC ^{[1
]}

Debler, J ^{[1
]}

Riegger, GA ^{[1
]}

Krämer, BK ^{[1
]}

机构：

[1] Univ Regensburg, Klin & Poliklin Innere Med 2, D-8400 Regensburg, Germany

来源：

LANCET | 2004年 / 364卷 / 9444期

关键词：

D O I：

10.1016/S0140-6736(04)17265-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1486 / 1487

页数：2

相关论文

共 50 条

[31] Nimesulide and COX-2 inhibitors
Bakhle, YS
LANCET, 1999, 354 (9180): : 772 - 772
[32] Selective inhibitors of COX-2
不详
EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (01) : 79 - 80
[33] No redemption for COX-2 inhibitors
Dorey, Emma
CHEMISTRY & INDUSTRY, 2006, (23) : 7 - 7
[34] COX-2 inhibitors in oncology
Haller, DG
SEMINARS IN ONCOLOGY, 2003, 30 (04) : 2 - 8
[35] Pharmacology of COX-2 inhibitors
Isakson, PC
COX-2: A NEW TARGET FOR CANCER PREVENTION AND TREATMENT, 2003, 37 : 25 - 51
[36] Selective COX-2 inhibitors
Parnham, MJ
DRUG NEWS & PERSPECTIVES, 1997, 10 (03) : 182 - 187
[37] COX-2 inhibitors - Reply
Hawkey, CJ
LANCET, 1999, 353 (9162): : 1440 - 1440
[38] Selective COX-2 inhibitors
Lloyd, AW
DRUG DISCOVERY TODAY, 1997, 2 (03) : 122 - 122
[39] Defining COX-2 inhibitors
Lipsky, PE
JOURNAL OF RHEUMATOLOGY, 2000, 27 : 13 - 16
[40] Nomenclature for COX-2 inhibitors
Vane, JR
Warner, TD
LANCET, 2000, 356 (9239): : 1373 - 1374

← 1 2 3 4 5 →